Skip to content

HEParin Antagonisation in Transcatheter Aortic Valve Implantation

Heparin Influence on Anticoagulation and Perioperative Hemostasis During Transfemoral Transcatheter Aortic Valve Implantation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05422170
Acronym
HepaTAVI
Enrollment
50
Registered
2022-06-16
Start date
2022-07-01
Completion date
2023-04-01
Last updated
2022-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis, Protamine Sulfate Overdose, Transcatheter Aortic Valve Implantation

Keywords

Anticoagulation

Brief summary

Unfractioned heparin is usually given in a defined dosage during transfemoral TAVI. Activated Clotting Time (ACT) is usually used to measure the heparin effect. ACT-analysis is easy to perform at the bedside, but susceptible to interference effects. At the end of the procedure, protamine is given to reverse eventual residual heparin effect. An overdose of protamine can impair the coagulation itself. The investigators want to analyse the effect of a partial heparin reversal by ROTEM Analysis.

Interventions

None listed

Sponsors

Deutsches Herzzentrum Muenchen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Severe aortic valve Stenosis * transfemoral TAVI as best therapy option * unfractioned heparin for periprocedural anticoagulation

Exclusion criteria

* known hypersensitivity /allergy to unfractioned heparin or protamine * acute systemic infection * pre procedural started and ongoing intravenous therapy with unfractioned heparin * severe periprocedural adverse event with the need for emergency surgery (with or with our CPB) * refusal of the patient to participate

Design outcomes

Primary

MeasureTime frameDescription
Primary endpointPeriproceduralVariability of the ROTEM CT(INTEM) after partial heparin reversal

Countries

Germany

Contacts

Primary ContactPatrick Mayr, MD
mayrp@dhm.mhn.de+498912180
Backup ContactMichael Joner, Prof
joner@dhm.mhn.de+498912180

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026